Biotechnology GSK Reveals New Phase 3 Data For Jemperli Combo Therapy To Support Expanded Use Approval For Wider Endometrial Cancer – GSK (NYSE:GSK) Read more
Biotechnology AstraZeneca Says Lynparza/Imfinzi Combo Shows Strong Clinical Benefit Vs. Chemotherapy In Endometrial Cancer – AstraZeneca (NASDAQ:AZN) Read more